Article
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments.
PRESS RELEASE
LAVAL, Quebec
,
April 1, 2015
/PRNewswire/ --
Valeant Pharmaceuticals International, Inc.
(NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of
Salix Pharmaceuticals, Ltd.
Salix Pharmaceuticals
is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), APRISO® (mesalamine), UCERIS® (budesonide) extended release tablets and RELISTOR® (methylnaltrexone bromide).
About
Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc.
(NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about
Valeant Pharmaceuticals International, Inc.
can be found at www.valeant.com.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
